[{"id":"9d1d5f8f-7b04-49f6-9e8a-92b8e7a77fa3","acronym":"KEYNOTE-D38","url":"https://clinicaltrials.gov/study/NCT05077709","created_at":"2021-10-14T19:57:33.332Z","updated_at":"2025-02-25T16:16:45.691Z","phase":"Phase 2","brief_title":"IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC","source_id_and_acronym":"NCT05077709 - KEYNOTE-D38","lead_sponsor":"IO Biotech","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Cylembio (imsapepimut and etimupepimut, adjuvanted) • IO103"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 02/14/2022","start_date":" 02/14/2022","primary_txt":" Primary completion: 01/04/2024","primary_completion_date":" 01/04/2024","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2024-07-23"},{"id":"6c84103e-94f8-45d1-b084-4f1170d64d4f","acronym":"KEYNOTE-D18","url":"https://clinicaltrials.gov/study/NCT05155254","created_at":"2021-12-13T14:12:44.051Z","updated_at":"2025-02-25T16:17:02.361Z","phase":"Phase 3","brief_title":"IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)","source_id_and_acronym":"NCT05155254 - KEYNOTE-D18","lead_sponsor":"IO Biotech","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Cylembio (imsapepimut and etimupepimut, adjuvanted) • IO103"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 407","initiation":"Initiation: 05/17/2022","start_date":" 05/17/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-01-09"},{"id":"b8123c42-b90f-4d8a-b03b-683f5cd5c248","acronym":"","url":"https://clinicaltrials.gov/study/NCT03939234","created_at":"2021-01-18T19:23:51.682Z","updated_at":"2024-07-02T16:36:16.853Z","phase":"Phase 2","brief_title":"Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.","source_id_and_acronym":"NCT03939234","lead_sponsor":"Lars Møller Pedersen","biomarkers":" IGH","pipe":"","alterations":" ","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IO103 • IO120"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/26/2019","start_date":" 04/26/2019","primary_txt":" Primary completion: 03/15/2021","primary_completion_date":" 03/15/2021","study_txt":" Completion: 03/15/2021","study_completion_date":" 03/15/2021","last_update_posted":"2022-02-21"},{"id":"59268b77-bb30-4adf-a5d0-4fd49befb347","acronym":"","url":"https://clinicaltrials.gov/study/NCT03714529","created_at":"2021-01-18T18:12:27.097Z","updated_at":"2024-07-02T16:36:40.289Z","phase":"Phase 2a","brief_title":"A Study of IO103 in Montanide Adjuvant for Basal Cell Carcinoma","source_id_and_acronym":"NCT03714529","lead_sponsor":"Herlev and Gentofte Hospital","biomarkers":" PD-L1 • CD8","pipe":"","alterations":" ","tags":["PD-L1 • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IO103"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 11/01/2018","start_date":" 11/01/2018","primary_txt":" Primary completion: 02/05/2020","primary_completion_date":" 02/05/2020","study_txt":" Completion: 02/05/2020","study_completion_date":" 02/05/2020","last_update_posted":"2020-10-08"},{"id":"1dcb1a45-731a-476e-864c-f34a66de2ebb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03042793","created_at":"2021-01-18T14:59:00.584Z","updated_at":"2024-07-02T16:36:43.614Z","phase":"Phase 1","brief_title":"Vaccination With PD-L1 Peptide Against Multiple Myeloma","source_id_and_acronym":"NCT03042793","lead_sponsor":"Lene Meldgaard Knudsen","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IO103"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 02/01/2017","start_date":" 02/01/2017","primary_txt":" Primary completion: 05/14/2020","primary_completion_date":" 05/14/2020","study_txt":" Completion: 05/14/2020","study_completion_date":" 05/14/2020","last_update_posted":"2020-07-07"}]